Novel theranostic tool allows for noninvasive identification and treatment of ovarian cancer

HMN 2024 – A radiotheranostic platform that employs a MUC16-targeting humanized antibody, huAR9.6. Ovarian cancer cells that express hypoglycosylated MUC16 residues are detected via the diagnostic radioligand, [89Zr]Zr-DFO-huAR9.6. The therapeutic counterpart, [177Lu]Lu-CHX-A”-DTPA-huAR9.6, demonstrated potent anti-tumor responses in preclinical models. Credit: Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.123.266524 A new radiotheranostic system has the ability to detect and treat […]

Read More